Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News XORTX Therapeutics Inc XRTX


Primary Symbol: V.XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:XRTX)

XORTX Announces Publication of Key Research in ADPKD

GlobeNewswire 2 days ago

XORTX Welcomes New Member to the Board of Directors

GlobeNewswire April 8, 2024

XORTX Announces Participation in Spring 2024 Investor Conferences

GlobeNewswire April 8, 2024

XORTX Announces New Clinical Advisory Board Member

GlobeNewswire March 27, 2024

XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial

TheNewsWire March 19, 2024

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

GlobeNewswire March 19, 2024

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

GlobeNewswire March 11, 2024

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

GlobeNewswire March 4, 2024

XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units

GlobeNewswire February 15, 2024
View More News ››

Opinion & Analysis (TSXV:XRTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:XRTX)

XRTX.v Unveils 2023 Milestones and 2024 Objectives

Yesterday, the pharmaceutical company XORTX Therapeutics Inc. (XRTX.v XRTX) shared its progress in 2023 and goals for 2024, mainly...
StockHawk1 - March 20, 2024

XORTX Highlights Achievements of 2023

CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV...
Betteryear2 - March 19, 2024

use Bluestar BioAdvisors est. net sales to calc a CF NPV

XRx-008 Program Highlights – Independent Commercial Assessment In support of ongoing pharmaceutical partnership discussions, XORTX...
KOkidneydisease - March 19, 2024

New Patent for Treatment of Chronic Kidney Disease Submitted

Xorlo program which is in a Phase 2/3 trial in patients with stage 2-4 ADPKD.   XRTX is continuing to scale up...
waves1 - March 15, 2024

Health Tech: Breakthroughs in Polycystic Kidney Disease and

With a primary focus on polycystic kidney disease and diabetic kidney disease, XORTX Therapeutics (XRTX.v XRTX) is advancing clinical...
StockHawk1 - March 12, 2024

$14/share Price Target from Alliance Global Partners

New on my Radar: XORTX Therapeutics (NASDAQ/TSXV: XRTX) - $14/share Price Target from Alliance Global Partners   In developing...
waves1 - March 8, 2024
View more Bullboard ››

Vertiqal Studios Corp.

Vertiqal Studios Corp.

Vertiqal Studios is a leading global digital media entertainment, production, and distribution company redefining the ...
View More »